Background {#Sec1}
==========

Lung cancer is one of the leading causes of cancer death worldwide. Despite recent advances in cancer treatment, the prognosis of lung cancer is not sufficient compared with that of other solid organ tumors \[[@CR1]\]. Even after complete surgical resection, the 5-year survival of early-stage non-small cell lung cancer (NSCLC) patients is only approximately 65% \[[@CR2]--[@CR4]\]. This poor prognosis is due to the high recurrence after resection \[[@CR5], [@CR6]\], which supports the presence of occult metastases. The survival benefit of adjuvant platinum-based chemotherapy has been established in stage II--III NSCLC \[[@CR7]--[@CR9]\]; however, there is no data supporting the use of adjuvant treatments for stage IA NSCLC, and the use of adjuvant chemotherapy for stage IB NSCLC is controversial \[[@CR10]\]. Recently developed molecular biomarkers predict only non-squamous NSCLC \[[@CR11], [@CR12]\], and no biomarkers for squamous cell carcinoma (SCC) have reached the validation stage. Therefore, in the setting of lung cancer, the identification of biomarkers for predicting the outcome after surgery and selecting patients who could benefit from adjuvant chemotherapy is crucial.

A breakdown in the cell cycle machinery induces the uncontrolled proliferation of tumors. This process is initiated by a variety of molecules in a cascade that activates the cyclin-dependent kinases (CDKs), which play a role in the progression of the cell cycle. On the molecular level, the activity of CDKs is regulated by subunits known as cyclins, and by phosphorylation and dephosphorylation of key residues, for example, Thr14, Tyr15, and Thr160 in CDK2 \[[@CR13]\]. A series of pathological investigations of the molecules that stimulate CDKs have clearly demonstrated their clinical significance for cancer diagnosis and treatment. For example, clinical evidence has indicated that the overexpression of cyclin E and cyclin B, which bind to and activate CDK2 and CDK1, respectively, correlates with tumorigenesis, prognosis, and sensitivity to chemotherapy in a variety of malignancies, as does the inactivation of CDK inhibitors, such as p21WAF1 and p27Kip1 \[[@CR14]--[@CR20]\]. The pairing between the CDK and cyclin isotypes is specific. However, the amount of cyclin protein did not correspond perfectly with CDK activity in our investigation (data not shown). Similar results regarding the association between cyclin E and the activity of its associated kinase were reported by another group \[[@CR21]\]. Therefore, we hypothesized that the direct measurement of CDK activity might produce relevant clinical indications for cancer diagnosis and treatment. Previously, we reported that the CDK-based risk score (C2P® assay, Sysmex, Japan) predicted the risk of distant recurrence in early breast cancer patients \[[@CR22]\]. The C2P® assay is determined using a combination of the specific activity of CDK1 (CDK1SA) and CDK2 (CDK2SA). The feasibility of this assay was confirmed in a cohort study in Caucasian breast cancer patients \[[@CR23]\] and in colon cancer patients \[[@CR24]\]. CDKSAs were also significantly associated with a pathologically complete response (pCR) after weekly administration of paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in breast cancer \[[@CR25]\].

In lung cancer, many cell cycle-related molecules have been reported to be correlated with prognosis \[[@CR26]--[@CR31]\]. Here, we investigated whether the activity of CDK1 and CDK2 could predict the recurrence of NSCLC or the death of stage I and II NSCLC patients.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This blinded cohort study was approved by the local ethics committees of Tohoku University and Hyogo Cancer Centre. All patients provided written informed consent. A total of 213 patients who were newly diagnosed with pathologically confirmed NSCLC at the two centers were enrolled in this study. The eligibility criteria were as follows: SCC, adenocarcinoma, and stage I--II disease. All patients underwent complete resection, and none received adjuvant or neoadjuvant chemotherapy. CDK1SA and CDK2SA were determined in 171 samples using a C2P® assay (Sysmex, Kobe, Japan), and the results were subjected to statistical analysis to evaluate recurrence or death as a clinical outcome. Tumor tissue was dissected immediately after resection, snap-frozen and stored at -80°C at each facility. Then, the samples were sent to the Sysmex Corporation (Kobe, Japan) and subjected to the C2P® assay. Tissues with extreme blood contamination were excluded from this study, because the expression level of CDKs is underestimated in the presence of more than 1600 ng/μL of hemoglobin. The histologic types were centrally reviewed at Tohoku University.

Patients {#Sec4}
--------

A total of 213 patients with primary NSCLC who had undergone surgery between July 2000 and September 2009 were recruited for this study. Twenty-four cases were excluded due to extreme blood contamination of the samples. C2P® assay measurements were performed on 189 frozen samples; in 18 cases, the CDK expression levels were below the detection threshold, and these samples were excluded from the analysis. Finally, 171 cases were subjected to statistical analyses, including 53 SCCs and 118 adenocarcinomas. The median follow-up period was 43.9 months (70--2820 days).

Measurement of CDK1SA and CDK2SA {#Sec5}
--------------------------------

The C2P® assay \[[@CR15], [@CR22]\] was used to measure the specific activity of CDKs. In brief, lysates of freshly frozen samples were applied to the wells of a 96-well PVDF filter plate (Millipore, Billerica, MD, USA). The expression of CDK protein was detected quantitatively by sequential reactions with primary anti-CDK antibodies, biotinylated anti-rabbit antibodies and fluorescein-labeled streptavidin. To measure the kinase activity, CDK molecules were immunoprecipitated from the lysate using protein beads. CDK SA activity (maU/eU) was calculated as CDK activity units (maU/μL lysate), which were divided by their corresponding CDK expression units (eU/μL lysate). maU (CDK activity unit) and eU (CDK expression unit) were defined as the enzyme activity and expression equivalent to 1 ng of recombinant kinase, respectively. When the expression level was lower than the detection limit of the assay, the case was excluded from the analysis. The detection limits for the expression level of CDK1 and CDK2 are 0.1 and 0.003 eU/μL lysate, respectively.

Statistical analysis {#Sec6}
--------------------

Recurrence-free survival (RFS) was calculated from the date of surgery to the date of first local or distant recurrence; patients who were alive without recurrence at the time of data collection and those who died without any evidence of the disease on the date of death were censored. The overall survival (OS) was calculated from the date of surgery to the date of death; patients who were alive were censored.

The data were analyzed using MedCalc version 12.3 (MedCalc Software, Ostend, Belgium), and survival between the groups was compared using the Kaplan-Meier method and an unstratified Cox proportional hazards model or the log-rank test. Correlation tables were analyzed using the chi-square test. Receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC) for the compared models were computed to simulate predictive accuracy.

Possible prognostic variables that were analyzed in this study included age (≥70 *vs* \<70 years), sex (male or female), tumor size (\>3 *vs* ≤3 cm), nodal status (negative or positive), pathological stage (≥IB *vs* IA), histological type (SCC or adenocarcinoma), CDK1SA (≥12.6 *vs* \<12.6) and CDK2SA (≥222 *vs* \<222). A value of *p* \<0.05 was considered significant.

Results {#Sec7}
=======

We obtained fresh-frozen samples from 213 cases from two centers: Tohoku University Hospital and Hyogo Cancer Centre. Twenty-four cases were excluded due to extreme blood contamination. The C2P® assay was performed on 189 frozen samples (see Additional file [1](#MOESM1){ref-type="media"}); in 18 cases, the CDK expression levels were below the detection threshold, and these cases were excluded from the analysis (assay success rate =90%). Finally, 171 samples were subjected to statistical analysis (Figure [1](#Fig1){ref-type="fig"}). The patients who were analyzed included 106 (62%) males and 65 (38%) females, with a median age of 70 years (38--86) (Table [1](#Tab1){ref-type="table"}). The median tumor size was 3.0 cm (0.9--10.0). A total of 150 cases (88%) were node-negative, and 21 cases (12%) were positive. The histologic type was centrally confirmed as SCC in 53 cases (31%) and adenocarcinoma in 118 cases (69%). The overall recurrence rate and overall survival rate at final follow-up were 22% (local, 8%; distant, 14%) and 78% (133/171), respectively. Thirty-five out of 37 recurrent cases received platinum-based chemotherapy. The distribution of CDK1SA and CDK2SA did not vary significantly between the two independent cohorts based on the chi-square test (*p* =0.2102 and *p* =0.3557, respectively; Table [2](#Tab2){ref-type="table"}). To examine the prognostic significance of the CDK1SA and CDK2SA results, ROC analysis was performed with overall recurrence as a clinical outcome.Figure 1**Flow chart of patient enrolment and reasons for exclusion.**

###### 

**Clinical and pathological characteristics of patients**

                            Total collective   Tohoku University   Hyogo Cancer Centre   
  ------------------------- ------------------ ------------------- --------------------- ----------
  Frozen blocks available   213                111                 102                   
  Successful CDK assay      171                90                  81                    
  Sex                       Male               106 (62%)           57 (63%)              49 (60%)
                            Female             65 (38%)            33 (37%)              32 (40%)
  Age                       \< 70 years        83 (49%)            43 (48%)              40 (49%)
                            ≥ 70 years         88 (52%)            47 (52%)              41 (51%)
  Tumor size                ≤ 3 cm             95 (56%)            52 (58%)              43 (53%)
                            \> 3 cm            76 (44%)            38 (42%)              38 (47%)
  pN                        \-                 150 (88%)           83 (92%)              67 (83%)
                            \+                 21 (12%)            7 (8%)                14 (17%)
  Stage                     IA                 89 (52%)            48 (53%)              41 (51%)
                            IB                 45 (26%)            28 (31%)              17 (21%)
                            IIA                31 (18%)            11 (12%)              20 (25%)
                            IIB                6 (4%)              3 (3%)                3 (4%)
  Histology                 Adenocarcinoma     118 (69%)           58 (64%)              60 (74%)
                            SCC                53 (31%)            32 (36%)              21 (26%)
  Recurrence                None               134 (78%)           81 (90%)              53 (65%)
                            Local              14 (8%)             3 (3%)                11 (14%)
                            Distant            23 (14%)            6 (7%)                17 (21%)
  Survival information      Alive              133 (78%)           75 (83%)              58 (72%)
                            Dead               38 (22%)            15 (17%)              23 (28%)

###### 

**Association between CDK-based risk groups and clinicopathological parameters**

               CDK1SA (cut-off = 12.6)   CDK2SA (cut-off = 222)                                           
  ------------ ------------------------- ------------------------ ------------- ---- ----- -------------- --
  Sex          Male                      57                       49                 76    30             
  Female       35                        30                       *p* =0.8817   55   10    *p =*0.0800    
  Age          \< 70 years               43                       40                 66    17             
  ≥ 70 years   49                        39                       *p =*0.7230   65   23    *p =*0.4888    
  Tumor size   ≤ 3 cm                    55                       40                 76    19             
  \> 3 cm      37                        39                       *p =*0.2955   55   21    *p =*0.3223    
  pN           \-                        85                       65                 118   32             
  \+           7                         14                       *p =*0.0759   13   8     *p =*0.1544    
  Stage        IA                        53                       36                 73    16             
  IB           25                        20                                     37   8                    
  IIA          12                        19                                     18   13                   
  IIB          2                         4                        *p =*0.1652   3    3     *p =*0.0267    
  Histology    Adenocarcinoma            64                       54                 101   17             
  SCC          28                        25                       *p =*0.9961   30   23    *p* \<0.0001   
  Facility     Tohoku Univ               53                       37                 72    18             
  Hyogo CC     39                        42                       *p =*0.2102   59   22    *p =*0.3557    

The area under the ROC curves (AUC) of CDK1SA (*p* =0.0498) and CDK2SA (*p* =0.4206) were 0.607 and 0.545, respectively, which indicated that CDK1SA, but not CDK2SA, was likely to be predictive of recurrence. The analysis revealed that the Youden Indexes for CDK1SA and CDK2SA were maximized at 12.6 maU/eU and 222 maU/eU, respectively. Therefore, these values were tentatively set as the cut-off points in this study. Coincidentally, the optimal cut-off value of lung cancer approximated that of our colon study (11 maU/eU) \[[@CR24]\]. The correlation analyses between CDKSA and the clinicopathologic parameters revealed that none of the parameters was associated with CDK1SA, while CDK2SA was significantly correlated with stage (*p* =0.0267) and histology (*p* \<0.0001) (Table [2](#Tab2){ref-type="table"}).

With a cut-off value of 12.6 maU/eU, the cases were classified as low CDK1SA (54%, 92 cases) or high CDK1SA (46%, 79 cases). In the Kaplan-Meier analysis, patients with low CDK1SA tumors showed significantly higher RFS than those with high CDK1SA tumors based on a log-rank test (Figure [2](#Fig2){ref-type="fig"}A, HR 2.26, 95% CI 1.18--4.32; *p* =0.0147); however, no prognostic value was observed (Figure [2](#Fig2){ref-type="fig"}B, *p* =0.0921).Figure 2**Analysis of recurrence and survival by risk category. (A)** Recurrence-free survival and **(B)** overall survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. **(C)** Recurrence- free survival and **(D)** overall survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.

CDK1SA and conventional clinicopathologic parameters, including sex (male *vs* female), age (\<70 *vs* ≥70), tumor size (≤3 cm *vs* \>3 cm), pathological lymph node status (positive *vs* negative), clinical stage (IA *vs* IB-IIB), and histology (SCC *vs* adenocarcinoma) were analyzed using a Cox proportional hazards model with recurrence or death as a clinical outcome (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Univariate analysis for recurrence revealed that sex (HR 2.53, 95% CI 1.16--5.52; *p* =0.0200), age (HR 2.80, 95% CI 1.36--5.77; *p* =0.0054), tumor size (HR 1.99, 95% CI 1.04--3.81; *p* =0.0380), pathological lymph node status (HR 3.20, 95% CI 1.51--6.77; *p* =0.0025), stage (HR 2.54, 95% CI 1.30--4.99; *p* =0.0070) and CDK1SA (HR 2.26, 95% CI 1.16--4.43; *p* =0.0177) were statistically significant (*p* \<0.05). Age, stage and CDK1SA remained significant by multivariate analysis for recurrence (Table [3](#Tab3){ref-type="table"}, age HR 3.06, *p* =0.0028; stage HR 2.16, *p* =0.0306; CDK1SA HR 2.25, *p* =0.0195). Even in the subgroup of 134 patients with stage IA and IB disease, CDK1SA but not CDK2SA had the prognostic power (Figures [3](#Fig3){ref-type="fig"}A and B, CDK1SA HR 2.56, *p* =0.0273; CDK2SA HR 1.18, *p* =0.7375). The Cox regression analysis revealed that CDK1SA was an independent predictor of recurrence (Table [5](#Tab5){ref-type="table"}, HR 2.57, 95% CI 1.08--6.09; *p* =0.0335).Table 3**Cox proportional hazards models for recurrence**Univariate analysisMultivariate analysisMultivariate analysisHR (95% CI)***p***valueHR (95% CI)***p***valueHR (95% CI)***p***valueSexMale2.53 (1.16--5.52)0.02001.99 (0.90--4.42)0.09132.00 (0.91--4.40)0.0876Age≥ 70 years2.80 (1.36--5.77)0.00543.06 (1.48--6.34)0.00282.79 (1.35--5.75)0.0056Tumor size\> 3 cm1.99 (1.04--3.81)0.0380pN+3.20 (1.51--6.77)0.0025Stage≥ IB2.54 (1.30--4.99)0.00702.16 (1.08--4.31)0.03062.23 (1.13--4.43)0.0222HistologySCC1.23 (0.62--2.44)0.5567CDK1SA≥ 12.62.26 (1.16--4.43)0.01772.25 (1.14--4.42)0.0195CDK2SA≥ 2221.82 (0.93--3.56)0.08371.53 (0.79--3.01)0.2165Table 4**Cox proportional hazards models for death**Univariate analysisMultivariate analysisMultivariate analysisHR (95% CI)***p***valueHR (95% CI)***p***valueHR (95% CI)***p***valueSexMale5.51 (1.96--15.46)0.00134.29 (1.50--12.30)0.00704.14 (1.45--11.78)0.0081Age≥ 70 years1.24 (0.66--2.35)0.5088Tumor size\> 3 cm2.36 (1.22--4.55)0.0111pN+2.82 (1.34--5.96)0.0069Stage≥ IB2.75 (1.39--5.44)0.00391.79 (0.87--3.71)0.11742.09 (1.03--4.24)0.0421HistologySCC2.49 (1.31--4.72)0.00531.53 (0.78--2.97)0.21561.23 (0.62--2.47)0.5555CDK1SA≥ 12.61.74 (0.91--3.32)0.09621.53 (0.79--2.97)0.2122CDK2SA≥ 2222.56 (1.34--4.87)0.00451.97 (1.00--3.87)0.0500Figure 3**Analysis of recurrence by risk category in stage I NSCLC. (A)** Recurrence-free survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. **(B)** Recurrence-free survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.

###### 

**Cox proportional hazards models for recurrence (Stage I)**

                            Univariate analysis   
  ------------ ------------ --------------------- --------
  Sex          Male         2.17 (0.85--5.53)     0.1050
  Age          ≥ 70 years   1.79 (0.75--4.24)     0.1908
  Tumor size   \> 3 cm      1.41 (0.59--3.35)     0.4413
  Stage        ≥ IB         1.67 (0.71--3.90)     0.2390
  Histology    SCC          1.10 (0.41--2.96)     0.8568
  CDK1SA       ≥ 12.6       2.57 (1.08--6.09)     0.0335
  CDK2SA       ≥ 222        1.19 (0.44--3.21)     0.7381

Regarding CDK2SA, which had a cut-off value of 222 maU/eU, the cases were classified as low CDK2SA (77%, 131 cases) or high CDK2SA (23%, 40 cases). Patients with low CDK2SA tumors showed significantly higher OS than those with high CDK2SA tumors based on a log-rank test (Figure [2](#Fig2){ref-type="fig"}D, HR 2.49, 95% CI 1.19--5.21; *p* =0.0033).

According to the univariate analysis for death, CDK2SA (HR 2.56, 95% CI 1.34--4.87; *p* =0.0045) was statistically significant along with sex (HR 5.51, 95% CI 1.96--15.5; *p* =0.0013), tumor size (HR 2.36, 95% CI 1.22--4.55, *p* =0.0111), pathological lymph node status (HR 2.82, 95% CI 1.34--5.96; *p* =0.0069) and stage (HR 2.75, 95% CI 1.39--5.44; *p* =0.0039). By multivariate analysis, sex, stage, and CDK2SA remained significant (sex HR 4.14, *p* =0.0081; stage HR 2.09, *p* =0.0421; CDK2SA HR 1.97, *p* =0.0500).

Subanalysis by histology revealed that the predictive value of CDK1SA for recurrence was stronger in adenocarcinoma than in SCC (Figure [4](#Fig4){ref-type="fig"}A and B, adenocarcinoma HR 2.26, *p* =0.0439; SCC HR 2.09, *p* =0.2182). On the contrary, in the SCC cases, the Cox regression analysis for recurrence revealed that only CDK2SA was statistically significant (Figure [4](#Fig4){ref-type="fig"}C and D, Table [6](#Tab6){ref-type="table"}, HR 3.86, 95% CI 1.05--14.2; *p* =0.0428).Figure 4**Analysis of recurrence by risk category in adenocarcinoma (A) (C) and SCC (B) (D). (A)(B)** Recurrence-free survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. **(C)(D)** Recurrence-free survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.

###### 

**Cox proportional hazards models for recurrence (SCC)**

                           Univariate analysis   
  ------------ ----------- --------------------- --------
  Sex          Male        NA                    
  Age          ≥70 years   1.48 (0.47--4.65)     0.5014
  Tumor size   \>3 cm      1.77 (0.48--6.52)     0.3905
  pN           \+          1.94 (0.59--6.44)     0.2793
  Stage        ≥IB         2.42 (0.54--10.99)    0.2530
  CDK1SA       ≥12.6       2.09 (0.63--6.91)     0.2286
  CDK2SA       ≥222        3.86 (1.05--14.17)    0.0428

NA, not analyzed due to bias (89% of SCC patients were male).

In the distribution of 35 recurrent cases on a scatter diagram with logarithmic scales according to CDK1SA and CDK2SA, we observed that the distribution of the non-survivors slightly shifted to the higher CDKSAs area (data not shown). This observation let us to perform Kaplan-Meier analyses, and it was found that the prognostic power of CDK2SA, but not of CDK1SA (Figure [5](#Fig5){ref-type="fig"}A), was significant in 35 patients who were treated with chemotherapy after recurrence (Figure [5](#Fig5){ref-type="fig"}B, HR for death 4.30, 95% CI 1.56--11.8; *p* \<0.0001).Figure 5**Analysis of survival by risk category in recurrent cases.** The zero timepoint indicates the diagnosis of recurrence. **(A)** Survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. **(B)** Survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.

Discussion {#Sec8}
==========

In this study, we demonstrated that CDK1SA and CDK2SA could identify individuals that were at high risk for recurrence and death among early-stage NSCLC patients after surgical resection. Even with complete resection, the prognosis of early-stage NSCLC is not good due to local and distant recurrence \[[@CR6]\], and it remains unclear which biomarkers are clinically useful for predicting recurrence, although some single molecules and gene signatures of non-squamous cell carcinomas are being validated in a large number of cohorts \[[@CR11], [@CR32]\]. Previously, cyclin expression and prognosis were reported to be correlated in lung cancer patients \[[@CR33]\]; however, this is the first study revealing that CDK activity is a promising predictor for early-stage NSCLCs. Furthermore, CDK1SA and CDK2SA are the first biomarkers that can be used to predict the prognosis of both adenocarcinoma and SCC. Because CDKs are the targets of new anti-cancer drugs and the development of many CDK inhibitors is underway \[[@CR34]\], this study will provide a basis for future personalized medicine using CDK inhibitors in NSCLC patients.

CDK1SA and CDK2SA have different implications in lung cancer. CDK1SA predicted recurrence after surgery, whereas CDK2SA predicted the overall survival of stage I and II NSCLC patients (Figure [2](#Fig2){ref-type="fig"}). Sub-analysis of 134 patients with stage IA and IB disease showed that CDK1SA was an independent predictor only for recurrence, but the power of prediction was much better than conventional criteria such as tumor size and stage (Figure [3](#Fig3){ref-type="fig"} and Table [5](#Tab5){ref-type="table"}). The clinical relevance of CDK1SA as a marker for recurrence prediction is in agreement with the conclusion of the colon study \[[@CR24]\]. In this colon study, CDK1SA was significantly elevated in microsatellite-stable tumors. Because most of colorectal cancers with stable microsatellites demonstrate chromosomal instability \[[@CR35]\], CDK1SA may have value as a marker of genomic instability. Genomic instability has been reported to predict clinical outcomes in multiple cancer types, including lung cancer \[[@CR36]--[@CR39]\]; therefore, prediction of recurrence demonstrated in this study may reflect the genomic instability of the tumors. According to sub-analysis by histology, the predictive value of CDK1SA for recurrence was greater in adenocarcinoma than in SCC (Figure [4](#Fig4){ref-type="fig"}A and B). Since adenocarcinoma is the most common histologic type of colon cancer, there is a similarity in the role of CDK1SA in colon and lung adenocarcinoma. Interestingly, Cox regression analysis for recurrence revealed that CDK2SA expression was statistically significant in SCC but not in adenocarcinoma (Figure [4](#Fig4){ref-type="fig"}C, D and Table [6](#Tab6){ref-type="table"}). This result suggests that CDK1 and CDK2 have different roles in adenocarcinoma and SCC.

In contrast to CDK1SA, CDK2SA predicted overall survival after surgery. This finding may be related to the chemo-sensitivity of the patients. Kaplan-Meier analysis indicated that the prognostic power of CDK2SA was significant in patients treated primarily with platinum-based chemotherapy after recurrence (Figure [5](#Fig5){ref-type="fig"}), suggesting that CDK2SA can predict platinum sensitivity/resistance. A similar trend was observed in our ovary study: tumors with high CDK2SA were more platinum-resistant in patients who underwent incomplete resection and subsequent platinum-based chemotherapy (unpublished data). The ability of cyclin E-associated kinase activity to predict the response to platinum-based chemotherapy in ovarian cancer patients was also reported by another group \[[@CR21]\]. In addition, inhibition of CDK2, but not CDK1, induced growth arrest in lung cancer cell lines through anaphase catastrophe \[[@CR40]\]. Taken together, these data indicate that CDK2 would be a good target for lung cancer treatment, and the measurement of CDK2SA could be useful for identifying patients who would receive the full benefit of CDK2 inhibitors.

A limitation of this study was that the number of cases in the sub-analysis for the outcome after platinum-based chemotherapy was low; however, the significant difference was quite clear (Figure [5](#Fig5){ref-type="fig"}). Prospective studies should be performed to clarify the predictive capacity of CDK2SA in platinum sensitivity/resistance in early-stage NSCLC patients after surgical resection.

In summary, this study suggested the possible clinical use of CDK1SA for recurrence prediction and CDK2SA for the prognosis of stage I and II NSCLC. Moreover, CDK2SA might be a predictor of platinum-based chemotherapy sensitivity/resistance. To the best of our knowledge, this is the first report that suggests a relationship between chemosensitivity and CDK activity in lung cancer. Thus, a combination of CDK1SA and CDK2SA might be helpful in decision-making regarding NSCLC treatment strategies.

Conclusions {#Sec9}
===========

CDK1SA is a predictor of recurrence and CDK2SA is a predictor of overall survival in early-stage NSCLC after surgery.
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Additional file 1: **Distribution of lung tumors according to CDK1SA and CDK2SA.** Adenocarcinoma cases and SCC cases are plotted on a scatter diagram with logarithmic scales according to CDK1SA and CDK2SA. Black square; the specific activity was defined as 0.5 when the activity of CDK is lower than the detection limit of the assay. The detection limits for the activity of CDK1 and CDK2 are 10 and 2 maU/μL lysate, respectively. (PDF 293 KB)
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